Evidence map›Paper›PMID 41886200›Full record

ReviewCurrent hypertension reports2026

Attributable Risk of Hypertension for Cardiovascular Disease.

Hunter P Mace, Donald Clark

Abstract readReview
In one paragraph

Review in Current hypertension reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hunter P MaceDepartment of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, US.
Donald ClarkDepartment of Medicine, Division of Cardiology, University of Mississippi Medical Center, Jackson, MS, US. dclark2@umc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewCardiovascular disease (CVD) remains the leading cause of mortality worldwide, and hypertension is a modifiable risk factor with the strongest association for developing heart disease. This review evaluates the attributable risk of hypertension for CVD at the population level and examines how this risk varies by demographic, geographic, and socioeconomic factors. Understanding the extent to which hypertension contributes to CVD can help inform targeted prevention and intervention treatment strategies. RECENT

findingsRecent studies have examined the attributable risk of hypertension for CVD across different populations. Hypertension had the highest population attributable risk (PAR) and population attributable fraction (PAF) values for overall CVD, stroke, heart failure, and coronary heart disease, especially among Black adults, younger individuals, and residents of low- and middle-income countries. Although hypertension prevalence has increased over time, some high-income countries have observed a decline in its attributable risk for CVD. This decline is likely due to improved blood pressure management and public health interventions. In the US, recent data shows blood pressure control among adults remains low. Population-level interventions such as sodium restrictions in the food supply, standardized treatment protocols to improve blood pressure control, and improved healthcare access have been shown to mitigate the burden of hypertension. Despite advancements in awareness and treatment, hypertension continues to be a major driver of the global CVD burden. The meaningful attributable risk for CVD highlights the need for improved public health protocols. Interventions that combine clinical management with population-level prevention strategies offer the greatest potential for reducing disparities and improving cardiovascular outcomes.

Indexed as

Cardiovascular DiseasesGlobal Burden of DiseaseHeart Disease Risk FactorsHypertensionHealth Status DisparitiesHumansSocioeconomic FactorsBlood pressureHypertension

Identifiers

PMID41886200
PMCPMC13021759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.